Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at [email protected].
The new educational initiative was launched to provide useful insights from dermatologists as well as personal accounts by patients with seborrheic dermatitis with many different backgrounds.
New research on the effects of the Canadian wildfires on asthma syndrome in patients sheds light on the downstream effects of ecological disaster on regions outside of those affected.
This new qualitative data may be helpful both for patient-centric decision-making for clinicians as well as endpoints in future research on prurigo nodularis.
This new data indicates that there may be potential for clinicians to maintain their typical lung cancer screening model’s accuracy and also reduce racial and ethnic disparities.
This new research concluded that the unclear nature of safety outcomes indicated additional research and enhanced monitoring of patients’ adverse events may be necessary.
The FDA's announcement requesting further study represents a step back in the process of 'neffy' becoming the first needle-free nasal spray epinephrine alternative.
This segment of Dr. Kim’s interview featured a discussion on the potential advantages and disadvantages of the new ARS-1 epinephrine nasal spray being considered by the FDA.
In a new interview with the HCPLive editorial team, Edwin H. Kim, MD, spoke about the new ARS-1 (Neffy) intranasal epinephrine spray for patients having Type 1 allergic reactions as well as the FDA's upcoming decision on the treatment.
These new results from the pivotal INTEGUMENT-PED trial met both of the investigators' primary and secondary endpoints.
In this interview segment, Jayme Heim, MRS, explored promising treatments on the horizon, hidradenitis suppurativa, and future research on teledermatology and artificial intelligence.
This interview with Jayme Heim featured a discussion about some of the latest treatment-related news for atopic dermatitis and psoriasis.
This new data expands upon limited current research on environmental elements that contribute to the extensive variation in symptoms and infection frequency seen in children.
This new Morbidity and Mortality Weekly Report on the CDC site indicates the importance of influenza vaccination, especially for at-risk populations.
These findings highlight the potential of dupilumab treatment in improving lung function among children that are shown to have uncontrolled, moderate-to-severe type 2 asthma.
This new data on dupilumab demonstrates the drug’s potential usefulness in treating type 2 inflammation, a role which is central to respiratory diseases including COPD.
The use of this scoring system twice-per-week may help patients to better manage their mild-to-moderate atopic dermatitis.
This new data suggests that while the Skindex-16 can help physicians to better assess severity of disease, greater levels of qualitative as well as quantitative research may be needed.
This research indicated that innocuous and noxious thermal as well as mechanical perception was shown to be diminished in lesions of HS patients, suggesting peripheral neuropathy.
The sNDA was announced for roflumilast cream 0.15% to the FDA, and the formulation is said to not to be disruptive to the skin barrier or contain common irritants to patients’ skin.
In new phase 2b/3 trial data, investigational IL-17A inhibitor izokibep did not meet its primary endpoint for patients with the chronic skin disease.
This new research indicates that children with ARDS surviving discharge have a higher probability of readmission than was reported previously among the pediatric intensive care unit population.
This research shows that a basophil activation test can support decision-making by clinicians when re-introduction of baked eggs in patients with allergies is a treatment being considered.
The new data addressed the lack of studies examining melanoma incidence despite the existence of research examining increases in relative numbers of advanced melanomas during the pandemic.
This research was the result of the first study assessing adaptive smoking cessation treatment within a clinical population using very few criteria for exclusion.
In this segment of her Q&A interview, Dr. Cotton discussed several major topics covered in her upcoming SHSA Conference presentation on pediatric HS.
This new Q&A interview with Dr. Cotton featured a discussion on the issues facing pediatric HS patients and other topics covered in her upcoming SHSA Conference presentation.
This new data had both a consistent long-term safety and tolerability profile with the previous short-term results for the skin disease, and there were no new safety signals recorded.
This test provides a useful approach as it can be less intensive for time and resources, less costly, and it can be conducted outside of the specialist allergy setting.
Given that this new research was an exploratory study with a smaller sample size, the study’s results may not be generalized and future studies should use more patients and institutions.
These new findings may help shape both the design and the use of an educational intervention on technology-based inhaler techniques for patients with pediatric asthma.
